Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR
- PMID: 15193410
- DOI: 10.1016/j.vaccine.2003.12.033
Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR
Abstract
The development of live attenuated vaccines, allowing for the safe and effective immunisation at mucosal surfaces, is a strategy of great interest for vaccinologists. The main advantage of this approach over conventional parenteral vaccines is the induction of strong mucosal immune responses, allowing targeting of the pathogen at the initial point of contact with the host. Further advantages include the ease of administration, high acceptance by vaccines, and relatively low production costs. Finally, well-characterised, safe and immunogenic vaccine strains are well suited as vectors for the mucosal delivery of foreign vaccine antigens and of DNA vaccines. However, such vaccines, when based on or containing genetically modified organisms (GMOs), are facing new and specific regulatory hurdles, particularly regarding the potential risks for humans and the environment. In this contribution we address selected aspects of the risk assessment of live attenuated bacterial vaccines covered in the course of the registration of vaccine strain CVD 103-HgR as a recombinant live oral vaccine against cholera.
Similar articles
-
A review of the current status of enteric vaccines.P N G Med J. 1995 Dec;38(4):325-31. P N G Med J. 1995. PMID: 9522876 Review.
-
[Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated Vibrio cholerae 01 strain: a double-blind study of Chilean adults].Rev Med Chil. 1993 Aug;121(8):857-63. Rev Med Chil. 1993. PMID: 8296092 Clinical Trial. Spanish.
-
Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.Lancet. 1988 Aug 27;2(8609):467-70. doi: 10.1016/s0140-6736(88)90120-1. Lancet. 1988. PMID: 2900401 Clinical Trial.
-
Vibrio cholerae CVD103-HgR live oral attenuated vaccine: construction, safety, immunogenicity, excretion and non-target effects.Dev Biol Stand. 1995;84:237-44. Dev Biol Stand. 1995. PMID: 7796960 Review.
-
[Cholera update and vaccination problems].Med Trop (Mars). 1998;58(2 Suppl):32-5. Med Trop (Mars). 1998. PMID: 9812307 French.
Cited by
-
Elimination of persistent vaccine bacteria of Salmonella enterica serovar Typhimurium in the guts of immunized mice by inducible expression of truncated YncE.PLoS One. 2017 Jun 19;12(6):e0179649. doi: 10.1371/journal.pone.0179649. eCollection 2017. PLoS One. 2017. PMID: 28628661 Free PMC article.
-
Perforin- and granzyme-mediated cytotoxic effector functions are essential for protection against Francisella tularensis following vaccination by the defined F. tularensis subsp. novicida ΔfopC vaccine strain.Infect Immun. 2012 Jun;80(6):2177-85. doi: 10.1128/IAI.00036-12. Epub 2012 Apr 9. Infect Immun. 2012. PMID: 22493083 Free PMC article.
-
Immunogenicity and protective efficacy of a live, oral cholera vaccine formulation stored outside-the-cold-chain for 140 days.BMC Immunol. 2020 May 25;21(1):29. doi: 10.1186/s12865-020-00360-1. BMC Immunol. 2020. PMID: 32450807 Free PMC article.
-
Use of oral cholera vaccine in complex emergencies: what next? Summary report of an expert meeting and recommendations of WHO.J Health Popul Nutr. 2007 Jun;25(2):244-61. J Health Popul Nutr. 2007. PMID: 17985828 Free PMC article.
-
Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice.Infect Immun. 2008 Oct;76(10):4554-63. doi: 10.1128/IAI.00532-08. Epub 2008 Aug 4. Infect Immun. 2008. PMID: 18678672 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
